ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

What symbol and exchange does Imagenebio shares trade?

Imagenebio trades on the NASDAQ stock market under the symbol IMA.

What is Imagenebio stock price doing today?

As of October 30, 2026, IMA stock price climbed to $4.10 with 4,092 million shares trading.

How much is Imagenebio worth?

IMA has a market cap of $46.54 million. This is considered a Sub-Micro Cap stock.

What are the top ETFs holding Imagenebio?

The top ETF exchange traded funds that IMA belongs to (by Net Assets): VTI, VXF, IWC.

Is Imagenebio (IMA) a good investment?

IMA has underperformed the market in the last year with a return of -53.4%, while the SPY ETF gained +10.9%. In the last 3 month period, IMA fell short of the market, returning -26.4%, while SPY returned +3.8%. However, in the most recent 2 weeks IMA has outperformed the stock market by returning +1.7%, while SPY returned -2.2%.

What are the support and resistance levels for Imagenebio (IMA)?

IMA support price is $3.82 and resistance is $4.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMA shares will trade within this expected range on the day.